<DOC>
	<DOCNO>NCT01121120</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness TXA127 accelerating time take patient recover platelet count follow Autologous Peripheral Blood Stem Cell transplant .</brief_summary>
	<brief_title>Acceleration Platelet Recovery Following Autologous Peripheral Blood Stem Cell Transplant ( PBSC ) Hodgkin , Non-Hodgkin Lymphoma Multiple Myeloma Patients</brief_title>
	<detailed_description>- This randomize , double-blind ( Investigator Study Subject ) , placebo-controlled study . - The condition regimen mobilization agent use discretion Study Center Investigator</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Subjects must least 18 year age Subjects must HL , NHL , MM require PBSCT Subjects must life expectancy least 4 month Subjects receive autologous PBSC transplant follow mobilization , CD34+ cell collect apheresis , condition chemotherapy Subjects must give write informed consent participate study . Consent must obtain prior performance studyspecific , noninstitutional standard procedure . A copy sign informed consent retain subject 's chart . Subjects must CD34+ collection allow reinfusion ≥1.5 x 106 ≤5.0 x 106 CD34+ cells/kg Subjects must psychological emotional state , view investigator , allow adherence protocol Female subject capable reproduction , male subject partner capable reproduction , must agree follow : Use effective contraceptive method course study 2 month follow last administration Investigational Product Female subject capable reproduction must negative beta human chorionic gonadotropin ( BHCG ) serum urine pregnancy test result within 7 day prior first Investigational Product dose Female subject surgically sterilize experienced menses least two year required pregnancy test Subjects receive radiotherapy pelvis and/or sternum within one year first Investigational Product administration Subjects previously receive planned Total Body Irradiation ( TBI ) Subjects history prior malignancy HL , NHL , MM remission &gt; 5 year , exception basal cell squamous cell carcinoma , cervical carcinoma situ biopsy , localized prostate cancer ( Gleason score &lt; 5 ) Subjects history myelodysplastic syndrome Subjects venous arterial embolic event AND receive anticoagulant treatment , event treatment within six month first Investigational Product administration Prior allogeneic hematopoietic cell transplant Presence uncontrolled infection infection require intravenous treatment within 7 day entry Female subject pregnant breastfeeding Subjects receive treatment investigational agent within 30 day project first administration Investigational Product ( Day 0 ) Subjects current alcohol use , illicit drug use , condition ( e.g. , psychiatric disorder ) , opinion Investigator , may interfere subject 's ability comply study requirement visit schedule Subjects know sensitivity Investigational Product component Subjects known seropositive HIV HTLVI Subjects prophylactic platelet transfusion , platelet count &gt; 10× 109/L , anticipate follow PBSC transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Lymphoma , Non-Hodgkin</keyword>
	<keyword>Hodgkin Disease</keyword>
	<keyword>Multiple myeloma</keyword>
	<keyword>Peripheral Blood Stem Cell Transplant</keyword>
	<keyword>Autologous Peripheral Blood Stem Cell Transplant</keyword>
	<keyword>Limited re-infusion CD34+ cell</keyword>
</DOC>